Background: In the NeoSphere trial, we assessed research-based PAM50 subtype predictors at baseline in all patients (pts), and at surgery (SX) in pts with residual disease (RD) to investigate the changes after treatment and the association with pCR and distant event free survival (DEFS). Methods: 417 HER2þ pts were randomized to neoadjuvant TD, TPD, TP or PD (T¼trastuzumab, P¼pertuzumab, D¼docetaxel), and received FAC/FEC and T after SX. 296 pts had RD. We assessed the intrinsic subtypes, ROR-P and ROR-S in 350 (83.9%) and 191 (64.5%) pts at baseline and SX respectively (166 paired samples). We evaluated the association with pCR and DEFS in the overall population and by ER status (161 (46.0%) ERþ; 189 (54%) ER-). Results: The intrinsic subtype distribution was different by ER status. After adjustment for ER, no significant association with pCR was found. None of the baseline biomarkers was associated with DEFS in the overall population. In ERþ, Her2-enriched (Her2E) subtype was associated with worst prognosis (HR 3.00 [1.10-8.22]; p ¼ 0.032). Higher ROR-P and ROR-S were significantly associated with higher risk of recurrence in ERþ only (test for interaction p ¼ 0.035 and p ¼ 0.012, respectively). At SX, there was a significant increase in LumA and a decrease in Her2E and LumB subtypes. ROR scores also decreased. In ERþ, post-treatment Her2E (HR 7.50 [1.86-30.1]; p ¼ 0.044) and LumB (HR 3.12 [1.03-9.94]; p ¼ 0.004) subtypes were associated with worst outcome than LumA. ROR-S and ROR-P were associated with outcome in ERþ tumors only (significant test for interaction). Compared to low-ROR-S group, high (HR 10.5 [2.79-39.3]; p ¼ 0.0005) and median ]; p ¼ 0.032) groups had higher recurrence risk. Five year-DEFS was 94%, 78% and 50% in the low, median and high ROR-S groups, respectively. In paired samples, the post-treatment biomarker assessment was more informative than at baseline. Conclusions: In the NeoSphere study, PAM50 provides different prognostic information in ERþ and ER-tumors. Pre-treatment biomarkers were less informative than post-treatment, reflecting their dynamic modulation. In ERþ tumors with RD, PAM50-derived scores assessed on surgical samples might identify patients who need treatment escalation. This warrants independent validation. Legal entity responsible for the study: Fondazione Michelangelo. Funding: Has not received any funding.
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